Sodium channel inhibitors, such as carbamazepine, phenytoin, oxcarbazepine, lamotrigine and TPM, are generally expected to be effective in treating epilepsy patients who have a mutation in SCN2A (Nav1.2). The gene discussed is SCN2A; the disease is epilepsy.